Previous close | 0.2500 |
Open | N/A |
Bid | 0.0000 |
Ask | 0.0000 |
Strike | 7.50 |
Expiry date | 2024-05-17 |
Day's range | 0.2500 - 0.2500 |
Contract range | N/A |
Volume | |
Open interest | 40 |
— So far this year alone, 25 TULSA-related scientific research presentations have been delivered at major medical meetings around the world — — Of those, eight (8) presentations were from leading urologists at AUA 2024 — — Clinical evidence continues to highlight TULSA’s ability to treat an unrivalled variety of patients with localized prostate cancer and/or BPH — TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-s
Key Insights Given the large stake in the stock by institutions, Profound Medical's stock price might be vulnerable to...
TORONTO, April 22, 2024 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets customizable, incision-free therapies for the ablation of diseased tissue, will announce its first quarter 2024 financial results after market close on Thursday, May 9, 2024. Profound management will host a conference call at 4:30 p.m. ET to review the financial results and discuss business developments in the